Cougar Implication
Cougar is a PIII company to be completed in 2015! It has completed a PII trials for prostate cancer.
J&J move show on Pharm industry is now taking in more risk.
This is a 1 Billion dollar deal. Lotz of money....
Valuation for biotech is so low now that, between partnering and takeover. Takeover makes more sense. No need to pay out royalties....
TLN buyer to get an irrefusable deal would have to 3,50$ and more - to cover initial dev. cost to original shareholders.
A conditional takeover like Bi-Par is envisaged with a floor price and a maximum price.
I don't see a piecemental deal where the 3 lead compounds are sold seperately.
I see buyer buying all 3 compounds as the two other will be viewed as "extra insurance".
232 results are to this date more impressive than any on the market for metastactic skin cancer. Yeah - metastatic.
232 is in the shadow of 4601... 232 has already demonstrate clinical efficacy.
Shigamabs is a low cost investment and high reward play.
FDA has already show how favorable they would be toward it...
It will cost 40M to dev and initial sales could be 500M with 50-75M recurrent sales.
Shigamabs is a low risk drug....
You also have Caprion which is now a money making machine...
Anyway...
I think the deal is obviously imminent.
How much will it be?
Within a week or so, Share price could rise to 1$ if market reacts to what's going on in the Oncology world.
Market can be late but will always recorrect accordingly.
The higher TLN goes the better the takeover price will be. If not we get only 3,50$.... Still an awesome return I note.